By identifying and tracking PVs, PhasED-Seq enables ctDNA MRD detection down to parts-per-million levels, providing levels of sensitivity that are significantly better than SNV-based methods. But detection is still challenging in low-disease burden states with existing methods, such as MRD detection at the end of therapy.įoresight's talk at ICML will introduce Phased Variant Enrichment & Detection Sequencing (PhasED-Seq), Foresight's proprietary ctDNA technology that leverages a novel class of somatic alteration called "phased variants" (PVs).
The presentation, titled "Phased variants improve DLBCL minimal residual disease detection at the end of therapy" will be presented during Session 3: Aggressive Lymphomas (Channel 3) on Sunday, June 20 at 17:45-19:15 (CEST).Ĭirculating tumor DNA (ctDNA) detection has prognostic value in DLBCL and has the potential to change the management of lymphoma in the clinic. We're proud that our abstract was selected for oral presentation at this year's ICML meeting and are excited to share this impactful data."ĭavid Kurtz, MD, PhD, Stanford University professor and Co-Founder of Foresight Diagnostics We believe that such early detection constitutes the future standard for ctDNA-guided patient monitoring and treatment in the clinic and for drug development applications. The oral presentation demonstrates the utility of Foresight Diagnostics' proprietary PhasED-Seq technology to improve MRD detection rates in DLBCL patients in low-disease burden settings.įoresight's MRD testing platform can detect relapsing disease 200 days earlier than current methods in DLBCL patients receiving first-line therapy.
Jun 18 2021įoresight Diagnostics, the emerging leader in blood-based lymphoma disease monitoring, announced today that clinical performance of its minimal residual disease (MRD) detection platform in diffuse large B-cell lymphoma (DLBCL) will be presented at the 16th International Conference on Malignant Lymphoma (ICML) on June 18-22, 2021.
0 kommentar(er)
